JOEL RICE: Open Payments
NPI 1013048800 · LONDON, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$250 in 11 payments from 9 companies in 2025. Trend: 2023 $93 · 2024 $325 · 2025 $250
Food & beverage: $250
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $52 |
| JAZZ PHARMACEUTICALS INC. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 1 | $30 |
| Lilly USA, LLC | 1 | $29 |
| Tempus AI, Inc | 1 | $29 |
| Genentech USA, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $17 |
| TOLMAR, INC. | 1 | $16 |
| pharmaand GmbH | 1 | $16 |
Products named: Trodelvy, ZEPZELCA, RUBRACA, VERZENIO, XT CDX, Tecentriq, Orserdu.
Industry payments across OH — which companies pay providers there.
